US venture capital (VC) firms deployed a record $412.7 billion in the first half of 2026, 30% more than the full year 2025 total, though much of that capital was concentrated in large deals. In this active financing environment, a priced round can provide new, market-based information about the value of a company’s securities. If that information could materially affect the fair market value of the common stock, the company should reassess whether its existing 409A valuation remains reasonable before granting additional options. The timing should reflect when the material financing information becomes sufficiently certain and available, rather than automatically being tied to the closing date.
This article addresses the reasons why a funding round would require a new 409A, what the material event rule means, a practical post-close timeline, what constitutes a funding event, and what to do if grants were made in a funding round prior to a new 409A being issued.
Why a Funding Round May Require a 409A Valuation Refresh
A valuation prepared under a Section 409A safe harbor generally creates a rebuttable presumption that the valuation is reasonable. However, reliance on such a presumption can become problematic if material information becomes available that could materially affect the value of the company’s stock. A bona fide, arm’s‑length priced financing provides current market evidence about the preferred stock issued in the round and may also affect the company’s equity value, capitalization table, and the allocation of value between preferred and common.
The preferred-stock price does not automatically represent the fair market value (FMV) of common stock. Preferred shares often have features like liquidation preferences, conversion rights, anti-dilution clauses, and other rights that common shares generally lack. If the financing or related information could materially affect the value of the common stock, the company should evaluate whether to obtain an updated 409A valuation before approving additional option grants or other stock-based awards.
A financing does not automatically invalidate the valuation used for earlier grants. However, it may affect whether the company can continue to rely on that valuation for later grants, and the regulations do not provide a fixed post-financing grace period. What matters is whether the transaction provides information that makes it unreasonable to continue relying on the older valuation.
How the 409A Material-Information Rule Works
Treasury Regulation §1.409A-1(b)(5)(iv)(B) provides rules for valuing stock that is not readily tradable on an established securities market. A valuation must use a reasonable application of a reasonable valuation method, and a prior valuation may no longer be reasonable if it fails to reflect material information that becomes available after the valuation date. The regulation does not prescribe a general deadline, such as 30 days, 60 days, or 90 days, within which a company must carry out a fresh valuation after a round of funding. Separately, a safe-harbor valuation generally cannot support the presumption of reasonableness for a grant date more than 12 months after the valuation’s effective date. This 12-month mark is the outer limit the safe harbor can stretch to, not a fixed date the company must refresh by, and not a guarantee it can wait that long if a material event happens sooner.
In practice, the company should begin assessing the financing once its material terms are sufficiently certain, rather than waiting automatically until closing. The significant date could vary depending on when the company receives relevant major transaction details, such as the price and terms.
The company is advised to consult its valuation expert, as well as tax or legal professionals, to find out if the financing demands a refresh. The factors taken into account in the analysis could include:
- Preferred stock price and terms of financing.
- Size and timing of the round.
- Revised capitalization table.
- Liquidation preferences and other investor rights.
- Changes in forecasts, revenue, cash, debt, or business prospects.
- Any secondary transactions or other market evidence.
Practical Timeline for Updating Your 409A After a Funding Round
Since there are no fixed regulatory timeframes, we have outlined below a sequence of practical measures that can help control risks:
- As soon as the financing is sufficiently certain: Inform the valuation expert and provide the related term sheets, financing documents, capitalization data, and updated financial information.
- At signing or closing: Check whether the transaction is significant and whether any information has already revealed that an earlier valuation might no longer be reasonable.
- Before new option grants: Determine, with input from the valuation provider and appropriate tax or legal advisers, whether continued reliance on the existing valuation remains reasonable.
- When the updated valuation is available: Approve the grants with the board or the appointed committee based on the updated FMV, and keep records that indicate the respective valuation and approval dates.
Valuation providers may quote a turnaround time of several weeks after receiving the complete documents. However, the actual timeline depends on the provider, the complexity of the company, and how the financing is structured. This is only an estimated service timeline and is by no means a regulatory deadline.
Which Funding Rounds Require a New 409A Valuation?
Not every cash receipt leads to a new 409A. Some transactions might provide important information and are worth reviewing:
- Priced equity rounds: Series A, B, C, or later financings set an agreed-upon price for a type of preferred stock.
- SAFE rounds and convertible notes: They may not establish a current fixed price for common stock at issuance, but valuation caps, discounts, conversion mechanics, and other terms may provide relevant information for the 409A analysis.
- Secondary transactions: Negotiated sales of existing shares might also be a source of market evidence, subject to the terms and participants involved in the transaction.
- Bridge rounds and extensions: They might need to be scrutinized if they affect the company’s valuation, capitalization, conversion terms, or investor rights.
- Strategic investments and venture debt with warrants: Valuation may be influenced by these factors, especially when an investor is offered equity-related rights.
- Tender offers: They may provide evidence of market pricing, but the price must be evaluated in light of the offer’s terms, participant eligibility, liquidity restrictions, and the rights attached to the shares.
The relevant question is not simply whether the company received cash, but whether the transaction reveals information that could materially affect the fair market value of its common stock.
Risks of Granting Options Before a 409A Refresh
An outdated valuation when granting the option doesn’t necessarily result in a Section 409A violation. However, there can be consequences if the exercise price is lower than the FMV of the underlying common stock on the Grant Date or if another Section 409A requirement has not been satisfied.
A Section 409A failure may result in current income inclusion, an additional 20% federal tax, and an interest-related additional tax for the affected service provider. The company may also face:
- Additional withholding or reporting obligations and employee-relations issues.
- Increased scrutiny during financing, M&A due diligence, tax reviews, or audits.
- Increased difficulty defending the valuation.
- The company may also incur professional fees and administrative costs when evaluating cancellation, replacement, amendment, repricing, or other corrective measures.
If you lose the safe harbor, you also lose the rebuttable presumption of reasonableness, and the valuation may become harder to defend.
Managing the Interim Period Before a 409A Update
If the updated valuation is not yet complete, companies should:
- Work together with the valuation provider, finance department, HR, and legal counsel.
- Tell hiring managers and equity administrators that grant approval may be delayed while the financing’s effect on the valuation is reviewed.
- Use offer letter language that clarifies that a future option grant will still be subject to the board’s approval and that the stock’s fair market value on the grant date will be used.
- Don’t promise a fixed exercise price before a grant receives board approval.
- Never backdate grants or approvals using a former valuation.
- Document the chronology of the financing, valuation correspondence, information provided to the appraiser, grant approvals, and decisions made during the interim period.
What to Do If Options Were Granted Before the Refresh
If options were granted before the company evaluated the financing’s effect on value:
- Obtain an updated valuation if appropriate and identify its effective valuation date. Do not assume that the updated valuation establishes FMV for earlier grants.
- Determine whether the exercise price for each grant was at least the FMV of the common stock on that grant date, using the facts and information available at the time.
- Review whether the financing information was available before the grants were approved.
- Consult tax and legal advisers about amendments, cancellations, replacements, repricings, or other corrective options.
- Record the financing chronology, correspondence related to valuation, information given to the appraiser, grant approvals, and decisions made during the period in between.
A later valuation may not, by itself, establish the FMV on an earlier grant date. The analysis must consider the applicable grant‑date facts.
FAQs: 409A Refresh After Funding Round
Here are some answers to the frequently asked questions related to a 409A refresh after a funding round:
Does a down round require a 409A refresh?
A priced down round is generally viewed as a material event under 409A that might lead to a new valuation prior to issuing more stock options. Nevertheless, the effect on common stock depends on the round’s terms, such as liquidation preferences and anti-dilution provisions, as well as the company’s prospects in general.
Does a higher preferred stock price always increase the 409A value?
Not necessarily. This depends on different factors such as a liquidation preference, cap table setup, and how you value your company using methods like OPM backsolve.
Does a 409A Valuation Have to Match the Funding Round Price?
No. The price in a funding round mostly reflects preferred stock, whereas the 409A valuation primarily determines the fair market value of the common stock.
Can a Company Use Its Preferred Stock Price as Its 409A Value?
No. There may be differences between the economic rights of preferred stock and common stock, such as liquidation preferences, conversion rights, or whether shares are voting. Such differences would be taken into account by a 409A valuation before determining the fair market value of common stock.
Keep Your 409A Valuation Aligned With Your Funding Activity
A funding round is not necessarily going to result in a requirement for a company to get a new 409A valuation. But, at the same time, it can supply material information that alters the analysis of the fair market value of common stock. Companies, therefore, should quickly evaluate the effects of the financing, consult their valuation advisers, and be sure the new equity grants are based on a justifiable and well-documented valuation.
For startups undergoing a financing event, getting the valuation process right can help minimize tax-related and compliance risks. It can also give companies greater confidence when granting equity to employees and other service providers. Cheqly partners with Eqvista to provide startups and growing companies with access to professional 409A valuation services. Through this partnership, companies can access expert valuation support as they raise funds and move through different stages of growth.